Potential impact of combined inhibition of 3a-oxidoreductases and 5a-reductases on prostate cancer  

作　　者：Michael V.Fiandalo Daniel T.Gewirth James L.Mohler 

机构地区：[1]Department of Urology,Roswell Park Comprehensive Cancer Center,Buffalo,NY,USA [2]Hauptman-Woodward Medical Research Institute,Buffalo,NY,USA

出　　处：《Asian Journal of Urology》2019年第1期50-56,共7页亚洲泌尿外科杂志（英文）

基　　金：This study was supported by the DoD Prostate Cancer Research Program Award(No.W81XWH-16-1-0635);the National Cancer Institute(NO.P01CA77739 and NO.R21CA205108)to James L.Mohler;Post-doctoral Training Award(No.W81XWH-15-1-0409)to Michael V.Fiandalo;DoD Synergistic Idea Development Award(No.W81XWH-14-1-0520)to Dan T.Gewirth;NCI Cancer Center Support Grant to Roswell Park Comprehensive Cancer Center for the Bioanalytics,Metabolomics and Pharmacokinetics,Pathology Network,and Genomics Shared Resources(No.P30CA016056).

摘　　要：Prostate cancer(PCa)growth and progression rely on the interaction between the androgen receptor(AR)and the testicular ligands,testosterone and dihydrotestosterone(DHT).Almost all men with advanced PCa receive androgen deprivation therapy(ADT).ADT lowers circulating testosterone levels,which impairs AR activation and leads to PCa regression.However,ADT is palliative and PCa recurs as castration-recurrent/resistant PCa(CRPC).One mechanism for PCa recurrence relies on intratumoral synthesis of DHT,which can be synthesized using the frontdoor or primary or secondary backdoor pathway.Androgen metabolism inhibitors,such as those targeting 5a-reductase,aldo-keto-reductase family member 3(AKR1C3),or cytochrome P45017A1(CYP17A1)have either failed or produced only modest clinical outcomes.The goal of this review is to describe the therapeutic potential of combined inhibition of 5a-reductase and 3a-oxidoreductase enzymes that facilitate the terminal steps of the frontdoor and primary and secondary backdoor pathways for DHT synthesis.Inhibition of the terminal steps of the androgen metabolism pathways may be a way to overcome the shortcomings of existing androgen metabolism inhibitors and thereby delay PCa recurrence during ADT or enhance the response of CRPC to androgen axis manipulation.

关 键 词：Androstanediol DIHYDROTESTOSTERONE DUTASTERIDE 3a-oxidoreductases Androgen deprivation therapy ABIRATERONE 

分 类 号：R73[医药卫生—肿瘤]